摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[5-methyl-2-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-3-quinoxalin-2-yl-urea | 457098-95-2

中文名称
——
中文别名
——
英文名称
1-[5-methyl-2-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-3-quinoxalin-2-yl-urea
英文别名
1-[5-Methyl-2-[(1-methylpiperidin-3-yl)methoxy]phenyl]-3-quinoxalin-2-ylurea
1-[5-methyl-2-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-3-quinoxalin-2-yl-urea化学式
CAS
457098-95-2
化学式
C23H27N5O2
mdl
——
分子量
405.5
InChiKey
HDMVAVYJHTYDLW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    79.4
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds useful for inhibiting CHK1
    申请人:Keegan S. Kathleen
    公开号:US20050245525A1
    公开(公告)日:2005-11-03
    Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
    本文披露了芳基和杂环芳基取代的类化合物,其可用于治疗与DNA损伤或DNA复制中的损伤相关的疾病和病症。本文还披露了制备这些化合物的方法,以及它们作为治疗剂的用途,例如治疗癌症和其他由DNA复制缺陷、染色体分离或细胞分裂引起的疾病。
  • COMPOUNDS USEFUL FOR INHIBITING CHK1
    申请人:Keegan Kathleen S.
    公开号:US20100105683A1
    公开(公告)日:2010-04-29
    Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
    本发明公开了用于治疗与DNA损伤或DNA复制中的损伤有关的疾病和病症的芳基和杂环基取代化合物。本发明还公开了制备该化合物的方法以及它们作为治疗剂的用途,例如,在治疗癌症和其他以DNA复制缺陷、染色体分离或细胞分裂为特征的疾病中。
  • Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
    申请人:Race Oncology Ltd.
    公开号:US10548876B2
    公开(公告)日:2020-02-04
    The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双或其衍生物、类似物或原药。
  • Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
    申请人:Race Oncology Ltd.
    公开号:US11147800B2
    公开(公告)日:2021-10-19
    The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双或其衍生物、类似物或原药。
  • ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS
    申请人:ICOS Corporation
    公开号:EP1379510B1
    公开(公告)日:2011-06-01
查看更多